Cellectis SA
cellectis.comWhat Do They Do?
Develops gene-edited cell therapy candidates for cancer and genetic diseases, and licenses its gene-editing technology and product rights to pharmaceutical and biotechnology companies.
20-F for FY2025, filed Mar 20, 2026We are a clinical stage biotechnological company, employing our core proprietary technologies to develop products based on gene-editing…View ↗
Together with our focus on immuno-oncology, we are using our gene-editing technologies to develop gene therapy product candidates for…View ↗
We are directly developing product candidates internally and have also entered into licensing relationships with AstraZeneca, Allogene, and…View ↗
We also have a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics, Inc. ("Iovance"), under which…View ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies license Cellectis's gene-editing technology and product rights; agreements name AstraZeneca, Allogene, Servier and Iovance.
20-F for FY2025, filed Mar 20, 2026We are directly developing product candidates internally and have also entered into licensing relationships with AstraZeneca, Allogene, and…View ↗
Under the AZ JRCA (as defined below), AZ Ireland has an exclusive right over certain therapeutic targets to pursue the development and…View ↗
Under the License Agreement dated March 8, 2019 between Allogene and us (the “Allogene License Agreement”), Allogene has exclusive rights…View ↗
We also have a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics, Inc. ("Iovance"), under which…View ↗
20-F for FY2025, filed Mar 20, 2026
Do Revenues Turn Into Profits?
No. It lost $67.6M in .
20-F for FY2025, filed Mar 20, 2026
20-F for FY2025, filed Mar 20, 2026
−$67.6MView ↗
How Are They Changing?
Exit from plant business
The older report described a plant-based synthetic-biology business through Calyxt. The latest report describes Calyxt as formerly owned and says Cellectis later sold its remaining equity in Cibus.
20-F for FY2022, filed Mar 14, 2023 20-F for FY2025, filed Mar 20, 2026We also own 48.6 % (as of February 28, 2023) of Calyxt, through which our Plants segment is carried out. Calyxt is a plant-based synthetic…View ↗
Who Do They Compete With?
Competes with Bristol-Myers Squibb, Gilead Sciences, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Fate Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Takeda Pharmaceutical, Mustang Bio, Atara Biotherapeutics, Adaptimmune, Poseida Therapeutics, Arcellx, Legend Biotech, BioNTech, Vor Therapeutics, Autolus Therapeutics, Lyell Immunopharma, and Editas Medicine
20-F for FY2025, filed Mar 20, 2026Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron…View ↗
Loading...
